Related Experiment Video
Updated: Aug 3, 2026
10:50
Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging
Published on: June 29, 2013
Microcirculation: target therapy in cardiovascular diseases - a clinical perspective
Ramon F Abarquez1, Jude Erric L Cinco
1Department of Medicine, Philippine General Hospital-College of Medicine, University of the Philippines, Manila, Philippines. cvlab@cm.upm.edu.ph
Clinical Hemorheology and Microcirculation
|January 16, 2004
Summary
Vascular mismatches can cause microvascular disease (MVD), impacting hypertension and coronary artery disease (CAD). Treatments like digitalis can mitigate MVD and apoptosis, potentially slowing heart failure progression.
Area of Science:
- Cardiovascular Physiology
- Pathology
Background:
- Microcirculation maintains tissue homeostasis through matched supply and demand.
- Stimuli can disrupt this balance, leading to vascular-capillary matrix-tissue mismatch.
- This mismatch can trigger compensatory hyperplasia or apoptosis.
Purpose of the Study:
- To explore the implications of vascular-capillary matrix-tissue mismatch.
- To investigate the role of microvascular disease (MVD) and apoptosis in cardiovascular conditions.
- To assess the therapeutic potential of agents like digitalis in managing these conditions.
Main Methods:
- The study discusses the physiological mechanisms of microcirculation regulation.
- It examines the pathological outcomes of supply-demand mismatch.
- It reviews the effects of pharmacological agents on cellular processes and disease progression.
Main Results:
- Microvascular disease (MVD) arises from supply-demand mismatch, with significant prognostic implications in hypertension and coronary artery disease (CAD).
- Apoptosis plays a crucial role in the development and progression of MVD.
- Digitalis and certain antihypertensive drugs exhibit anti-apoptotic and MVD-blunting effects.
Conclusions:
- Recognizing the role of apoptosis and MVD could shift clinical practice paradigms.
- These agents can control left ventricular hypertrophy (LVH) development.
- This control may reduce the progression of congestive heart failure (CHF).
Related Concept Videos
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...